Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01641081 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT01641081 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 174 participants.
The verdict
NCT01641081, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to moderate asthma. This study will include a screening visit followed by a 4 month treatment period.
Interventions
- DRUG Placebo
- DRUG Formoterol Fumarate in the Pressair DPI, Low Dose
- DRUG Formoterol Fumarate in the Pressair DPI, High Dose
- DRUG Foradil Aerolizer, Low Dose
- DRUG Foradil Aerolizer, High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01641081
The ClinicalTrials.gov registry entry for NCT01641081 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01641081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01641081 about?
NCT01641081 is a clinical study titled "Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma". The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to moderate asthma. This study will include a screening visit followed by a 4 month treatment period.
What is the current status of trial NCT01641081?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2012-06. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01641081?
The interventions under investigation include: Placebo (DRUG), Formoterol Fumarate in the Pressair DPI, Low Dose (DRUG), Formoterol Fumarate in the Pressair DPI, High Dose (DRUG), Foradil Aerolizer, Low Dose (DRUG), Foradil Aerolizer, High Dose (DRUG).
Who is sponsoring clinical trial NCT01641081?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.